Related Experiment Video
Updated: Sep 19, 2025
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
Isoniazid-induced hepatotoxicity in patients with latent tuberculosis - experience from a tuberculosis center
Bruno S Silva1, Beatriz Ferraz1, Nuno Faria2
1Pulmonology Department, Centro Hospitalar Universitário de Santo António, Largo do Professor Abel Salazar, 4099-001, Oporto, Portugal; Institute of Biomedical Sciences Abel Salazar, University of Oporto, Rua Jorge de Viterbo Ferreira, number 228, 4050-313, Oporto, Portugal.
Background:
Although the prevalence of isoniazid-induced hepatotoxicity (IIH) has been documented in patients with tuberculosis, its prevalence in latent tuberculosis infection (LTBI) patients is less studied. The aim of this study was to investigate the prevalence of IIH in a group of LTBI patients who received isoniazid monotherapy.
Methods:
Retrospective cohort study including patients who underwent isoniazid monotherapy for LTBI in an outpatient clinic between January 1st, 2020, and June 30th, 2021.
Results:
A total of 274 cases were analyzed. About half (50.4 %) were male; median age was 53 years-old (minimum: six; maximum 89). The most common comorbidities were dyslipidemia (25.5 %), body mass index between 25 and 30 kg/m2 (20.4 %), obesity (14.7 %) and chronic hepatic disease (CHD; 12.8 %). 47.4 % had systemic inflammatory diseases. Significant elevation of liver enzymes was documented in 27 % of patients. IIH was documented in 20.4 % of patients; there was a statistically significant relation with dyslipidemia (p < 0.001), CHD (p = 0.023), psoriasis (p = 0.025), spondyloarthropathies (p = 0.017) and male sex (p = 0.042). Dyslipidemia showed a strong correlation to IIH (adjusted odds ratio: 8.045).
Conclusion:
Patients with dyslipidemia had an adjusted odds ratio of 8.045 to develop IIH. Future multicentric studies should be started to better explore this relation, as well as treatment options.
Related Concept Videos
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:28Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:26Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:31Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...